Reumatologia最新文献

{"title":"Retrospective analysis of IgG4-related disease cases at a tertiary care centre in India","authors":"M. Bhatt, Sanchit Kumar, M. Soneja, S. Vyas, M. Tripathi, R. Kumar, Prabhjot Singh, M. Sharma, N. Wig","doi":"10.5114/reum.2022.113517","DOIUrl":"https://doi.org/10.5114/reum.2022.113517","url":null,"abstract":"Objectives IgG4-related disease (IgG4-RD) is a chronic inflammatory disorder with prominent fibrosis. This retrospective analysis was undertaken to study the clinical, laboratory, and radiological characteristics of patients with extra-pancreatic IgG4-RD and their response to treatment at a tertiary care centre located in northern India. Material and methods Patient data from our centre between January 2017 and January 2021 were reviewed. Probable/definite IgG4-RD cases were included in the analysis. Results A total of 14 cases were identified with a median age of 39 years (range 19–56 years). There were 10 males and 4 females. All patients presented with slowly progressive soft tissue swellings with pain/discomfort related to local mass effect. The median delay in diagnosis was 9.5 months (range 2–72 months). Cross-sectional imaging showed soft tissue masses in all cases. All contrast-enhanced studies (n = 7) showed enhancement on computed tomography and magnetic resonance imaging scan. F-18 fluorodeoxyglucose-avidity was observed in 8 of 9 (88.9%) cases. Biopsies performed in 12 of these were classified as definite in 8 and possible IgG4-RD in 4 cases. Patients were treated with a median dose of 1 mg/kg/day (range 0.5–1 mg/kg/day) prednisolone. Steroids were successfully tapered in all 12 cases with 41.6% (5 of 12) being off corticosteroids at a median follow-up of 10 months (range 0–18 months). Two patients were lost to follow-up. Conclusions IgG4-related disease is a chronic illness with a wide spectrum of manifestations, in which the diagnosis is often delayed, but it shows an excellent response to treatment. Efforts must be made to increase awareness among physicians about this disease to institute appropriate treatment as early as possible.","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88532586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term administration of immunoglobulin in a patient with anti-SRP immune-mediated necrotizing myopathy.","authors":"Filipe Oliveira Pinheiro, Pedro Madureira, Maria Seabra Rato, Lúcia Costa","doi":"10.5114/reum.2022.123675","DOIUrl":"https://doi.org/10.5114/reum.2022.123675","url":null,"abstract":"in quadriceps","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/47/RU-60-154876.PMC9847102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9146022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.","authors":"Mohammad Hassan Jokar,&nbsp;Bita Baghbani,&nbsp;Kiarash Roustai Geraylow,&nbsp;Jaleh Shariati,&nbsp;Hassan Mehrad-Majd,&nbsp;Zahra Mirfeizi,&nbsp;Kamila Hashemzadeh","doi":"10.5114/reum.2022.120757","DOIUrl":"https://doi.org/10.5114/reum.2022.120757","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic sclerosis (SSc) is an autoimmune, connective tissue disorder of unknown etiology which causes vasculopathy and fibrosis. Raynaud's phenomenon (RP) is a common complication of SSc, which leads to ischemia and gangrenes. Treatment of RP is a clinical problem and often remains insufficient.This study aimed to evaluate the therapeutic efficacy of local injections of botulinum toxin type A (BTX-A) in improving the symptoms of Raynaud's phenomenon (RP) secondary to scleroderma.</p><p><strong>Material and methods: </strong>This parallel single-blinded, placebo-controlled clinical trial enrolled 29 patients with scleroderma. Participants received BTX-A in the first, 2^nd, 3^rd, and 4^th dorsal web spaces and the base of the thumb and small finger of the non-dominant hand and 2.5 ml of sterile normal saline in the opposite hand. Pre-injection measurements and post-injection follow-up evaluations at months 1 and 4 were performed. We compared the outcomes using the paired Student's <i>t</i>-test.</p><p><strong>Results: </strong>The change in pain severity between pre-injection and month 1 follow-up was significantly larger in the BTX-A group (<i>p</i>-value = 0.04). Between pre-injection and month 1 and month 4, the changes in the Raynaud's condition score (RCS) (<i>p</i>-value = 0.02, 0.004, respectively) and the number of Raynaud's attacks (<i>p</i>-value = 0.006, 0.001, respectively) were significantly greater in the BTX-A group. No significant difference was found in terms of paresthesia, skin thickening, upper extremity function, ulcer diameter, number of ulcers, or Raynaud's attack duration between the two groups (<i>p</i>-value > 0.05). In time, the decrease in pain severity, paresthesia, RCS, number of ulcers, and ulcer diameter, and the increase in upper extremity function were significantly greater in the BTX-A group as compared to the placebo group (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Our study showed that local injection of BTX-A is safe and has beneficial therapeutic effects on RP and RP-related digital ulcers in SSc patients.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/ec/RU-60-152148.PMC9847105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10571848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of rheumatic and musculoskeletal diseases in a Nigerian peri-urban community: results of a cross-sectional survey using the COPCORD stage 1 model.","authors":"Adelowo Olufemi,&nbsp;Olaosebikan Babatunde Hakeem,&nbsp;Wright Kikelomo Olalade,&nbsp;Ogundele O Sunday,&nbsp;Adedeji O Oluwole","doi":"10.5114/reum.2022.123667","DOIUrl":"https://doi.org/10.5114/reum.2022.123667","url":null,"abstract":"<p><strong>Introduction: </strong>There is relative neglect of rheumatic and musculoskeletal diseases (RMDs) in sub-Saharan Africa (SSA). While hospital-based reports on RMDs abound, there is a paucity of population-based reports on these conditions which are otherwise recognized to cause functional disability and reduced quality of life in the affected individuals. Thus, the objective of this study is to determine the prevalence, diagnostic types, and predictors of musculoskeletal (MSK) pain in Agbowa, a peri-urban community in Lagos, South-West Nigeria.</p><p><strong>Material and methods: </strong>This community-based survey utilized the World Health Organisation/International League of Association of Rheumatology Community Oriented Programme for the Control of Rheumatic Diseases (WHO/ILAR COPCORD) stage 1 model. All respondents had their profiles documented via modified COPCORD questionnaires. Pain intensity and functional disability were assessed by the Numerical Rating Scale (NRS) and Health Assessment Questionnaires Disability Index (HAQ-DI) respectively. The rheumatic and musculoskeletal diseases were classified using relevant validated criteria. Data obtained were analysed using SPSS Version 21.</p><p><strong>Results: </strong>There were 3056 respondents who were predominantly female (59.2%). The period prevalence of MSK pain among the 3056 respondents was 58% (<i>n</i> = 1,773). There were significantly more females with MSK pain than males (62.8% vs. 37.2%, <i>p</i> = 0.001). Overall, 380 (12.4%) subjects had clinically diagnosed RMDs. The common RMDs in decreasing order were osteoarthritis (<i>n</i> = 185, 6.1%), chronic low back pain (<i>n</i> = 95, 3.1%) and soft tissue rheumatism (<i>n</i> = 52, 1.7%). The bivariate analysis showed that female sex, family history of MSK conditions, history of previous trauma, and some comorbidities were significantly associated with MSK pain. The median HAQ-DI was 0.6 (IQR 0.1-1.8) with significant disability (HAQ-DI ≥ 1) in 39.5% of the subjects.</p><p><strong>Conclusions: </strong>The burden and impacts of these conditions are considerable. Thus, the government needs to devise programmes and policies to limit the effects of RMDs in such communities.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/3b/RU-60-156144.PMC9847106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10581041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity.","authors":"Tulus Widiyanto,&nbsp;Rudy Hidayat,&nbsp;R M Suryo Anggoro Kusumo Wibowo,&nbsp;Hamzah Shatri","doi":"10.5114/reum.2022.119041","DOIUrl":"https://doi.org/10.5114/reum.2022.119041","url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis is associated with bone loss and the risk of osteoporotic fracture. Bone loss in this disease is mediated by inflammation and autoimmunity. Many studies have shown that anti-citrullinated protein antibody is capable of inducing bone loss through several mechanisms.This study aimed to determine the relationship between autoimmunity, represented by anti-mutated citrullinated vimentin (anti-MCV) in this study, and bone loss, represented by <i>C</i>-terminal cross-linking telopeptide of type I collagen (CTX-1), and <i>N</i>-terminal pro-peptide of type 1 procollagen (P1NP) in this study, in patients with rheumatoid arthritis in remission and low disease activity.</p><p><strong>Material and methods: </strong>This study enrolled 38 rheumatoid arthritis patients with disease remission and low disease activity in Cipto Mangunkusumo Hospital between August and September 2019. We collected the patients' demographic data, Disease Activity Score 28 (DAS28), and treatment history. All participants underwent blood work for anti-MCV, CTX-1, and P1NP.</p><p><strong>Results: </strong>Thirty-four of the subjects were women (89.5%), with the mean age of 40 ±7.6 years and the median disease duration of 36 months. Among the subjects, 26 patients (68.4%) were anti-MCV positive. There was no correlation between anti-MCV and CTX-1 levels (<i>r</i> = 0.101, <i>p</i> = 0.274). There was a moderate negative correlation between anti-MCV and P1NP (<i>r</i> = -0.449, <i>p</i> = 0.001). The mean difference of P1NP according to anti-MCV level also showed a significant difference (<i>p</i> = 0.019).</p><p><strong>Conclusions: </strong>The anti-MCV levels are not directly correlated with CTX-1 levels, indicating heterogeneity in the disease course even after inflammation has ceased. The anti-MCV and P1NP levels are moderately correlated, indicating that bone formation is resumed during the suppression of autoimmunity.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/36/RU-60-47705.PMC9494793.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40391036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical presentation, radiological findings and treatment options in Hughes-Stovin syndrome.","authors":"Melek Kechida,&nbsp;Syrine Daadaa,&nbsp;Walid Jomaa","doi":"10.5114/reum.2022.115666","DOIUrl":"https://doi.org/10.5114/reum.2022.115666","url":null,"abstract":"<p><p>Hughes-Stovin syndrome is a rare disease characterized by thrombophlebitis associated with arterial or bronchial aneurysms. Even though it was described first in 1911, it is scarcely reported in the literature. Hughes-Stovin syndrome diagnosis is based on clinical manifestations as well as radiological findings. There are no validated criteria or specific laboratory findings to confirm the diagnosis. Computed tomography pulmonary angiography remains the gold standard for the diagnosis and follow-up of radiological findings, as they were recently described in a critical analysis of the largest cohort in the literature. The aim of this review is to draw attention to this rare but potentially fatal disease and to discuss its therapeutic options.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/05/RU-60-46890.PMC9238307.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between platelet distribution width and disease activity in patients with polymyositis.","authors":"Gokhan Sargin,&nbsp;Ceren Demir,&nbsp;Songül Cildag,&nbsp;Taskin Senturk","doi":"10.5114/reum.2022.120760","DOIUrl":"https://doi.org/10.5114/reum.2022.120760","url":null,"abstract":"<p><strong>Introduction: </strong>Muscle enzymes are an indicator of ongoing muscle damage and disease activity in patients with idiopathic inflammatory myopathy. Although platelet-related parameters have been shown to be useful as markers of disease activity in autoimmune diseases, the relationship between platelet distribution width (PDW) and disease activity has not been previously studied in polymyositis. We aimed to determine the relationship between PDW and disease activity in patients with polymyositis.</p><p><strong>Material and methods: </strong>Twenty-seven patients with polymyositis and thirty healthy controls were included in the study. Disease activity was evaluated using the myositis disease activity assessment Visual Analogue Scale (MYOACT) and the Myositis Intention to Treat Index (MITAX). The relationship between PDW and disease activity was evaluated using Pearson's or Spearman's correlation and reliability was assessed using correlation coefficients.</p><p><strong>Results: </strong>The mean platelet volume (MPV) and plateletcrit (PCT) were significantly higher and PDW was significantly lower in patients with polymyositis compared to the control group. The mean PDW levels were lower in patients with constitutional symptoms and arthralgia/arthritis (<i>p</i> < 0.005). Although PDW levels were lower in patients with mechanical hand, lung involvement, or dysphagia compared to patients without, there was no statistically significant difference between them. Platelet distribution width was found to be negatively correlated with disease activity.</p><p><strong>Conclusions: </strong>We found that PDW was negatively correlated with MYOACT and MITAX, widely used tools in assessing the disease activity of polymyositis. Based on this, PDW may be utilized as a non-invasive potential index to assess disease activity in patients with polymyositis.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/ba/RU-60-48076.PMC9661407.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of intra-sacroiliac joint methylprednisolone injection in the recovery of patients with spondyloarthropathy: a randomized controlled trial.","authors":"Elham Rajaei,&nbsp;Khaled Bavieh,&nbsp;Karim Mowla,&nbsp;Ali Ghorbani,&nbsp;Nooshin Movaffagh","doi":"10.5114/reum.2022.120285","DOIUrl":"https://doi.org/10.5114/reum.2022.120285","url":null,"abstract":"<p><strong>Introduction: </strong>Spondyloarthropathies are a group of chronic inflammatory diseases with specific clinical symptoms in rheumatic diseases. These patients suffer from pain in the joints. Physicians have tried several ways to decrease the pain in these patients. This study aimed to evaluate the effect of intra-sacroiliac joint methylprednisolone injection under the guidance of ultrasonography in spondyloarthropathy patients.</p><p><strong>Material and methods: </strong>In this randomized control trial we studied 60 patients with spondyloarthropathy (30 patients in the intervention group and 30 patients in the control group) from January 2020 to December 2020. The intervention group patients received 40 mg of intra-sacroiliac joint (SIJ) methylprednisolone injection at the beginning in addition to treatment with nonsteroidal anti-inflammatory drugs (inflammatory dose) and sulfasalazine (2 to 3 g/day). Patients' pain intensity and symptoms were assessed in the 2^nd, 4^th, 6^th, and 8^th weeks after glucocorticosteroid injection. Quantitative factors were compared by independent Student's <i>t</i>-test. Data analysis was performed using SPSS version 22.0 software. A <i>p</i>-value < 0.005 was considered significant.</p><p><strong>Results: </strong>There were no statistically significant differences in Visual Analogue Scale (VAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) criteria and finger-to-floor (FTF) levels in the intervention and control groups. There were significant differences in VAS and BASDAI criteria and FTF levels 2 weeks after the injection, and this difference remained the same until the end of the 8^th week. The <i>p</i>-value was significant (<i>p</i>-value < 0.0001).</p><p><strong>Conclusions: </strong>The sacroiliac joint methylprednisolone injection approach with ultrasound guidance seems to be effective in pain relief and function, and patient satisfaction scores. Additionally using the guidance of ultrasonography in this approach is without the risk of radiation exposure.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/d1/RU-60-48004.PMC9661409.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crowdfunding campaigns for the needs of people with rheumatic diseases living in Poland: a retrospective study.","authors":"Mikołaj Kamiński,&nbsp;Aleksandra Borys,&nbsp;Paweł Hrycaj","doi":"10.5114/reum.2022.120759","DOIUrl":"https://doi.org/10.5114/reum.2022.120759","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with rheumatic diseases may require costly treatment and continuous rehabilitation, which Internet collections may finance. We aimed to characterize medical crowdfunding campaigns for the needs of Polish people with rheumatic diseases.</p><p><strong>Material and methods: </strong>We utilized data from the largest medical crowdfunding platform in Poland, Siepomaga.pl. All collections in the years 2009-2017 for the needs of people with rheumatic diseases were identified.</p><p><strong>Results: </strong>Twenty-three of 2,656 collections were included (0.9%). Sixty-five and two percent of campaigns collected the financial target. The median amount of collected funds was 3,369 euros. Ten collections concerned conservative treatments (drug and/or rehabilitation), seven financed surgery, five supported the acquisition of medical equipment or its repair, and one aimed at facilitating a diagnostic consultation with a foreign specialist.</p><p><strong>Conclusions: </strong>Polish patients with rheumatic diseases collect funds via medical crowdfunding, mostly for needs not covered by public healthcare or to obtain better health services in the private sector.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/6e/RU-60-48075.PMC9661406.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study.","authors":"Małgorzata Wisłowska","doi":"10.5114/reum.2022.115987","DOIUrl":"10.5114/reum.2022.115987","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of severe rheumatoid arthritis (RA) is currently based either on biological agents or Janus kinase/signal transducer and activator of transcription inhibitors, most often in combination with methotrexate (MTX).</p><p><strong>Aim of the study: </strong>The aim of the study was to compare the effectiveness and side effects of bio- logic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) DMARDs treatment.</p><p><strong>Material and methods: </strong>The analysis included 108 RA patients with active disease treated with MTX 25 mg per week. Eighty patients (group I) were treated with bDMARDs and 28 patients (group II) with JAK-STAT inhibitors. The duration of morning stiffness, pain on Visual Analogue Scale (VAS), 28-joints Disease Activity Score (DAS28) and Simplified Disease Activity Score (SDAI) were assessed. Classical radiographic images of patients' hands and feet using the Larsen and Dale's criteria were evaluated. The effects of treatment with bDMARDs and tsDMARDs were analyzed.</p><p><strong>Results: </strong>All studied patients presented at least Larsen and Dale's stage 3 of X-ray changes typical for RA. There were no statistically significant differences in disease duration, ESR, CRP, DAS28 and SDAI values between studied groups. Patients from group II previously used higher numbers of bDMARDs than group I treated with bDMARDs. Low disease activity after treatment was achieved by all patients; therefore patients from group II (treated with tsDMARDs) achieved lower values of patients' global assessment on VAS.</p><p><strong>Conclusions: </strong>The results of the present observational study indicated that treatment with JAK inhibitors is very promising. These drugs are not inferior in effectiveness to bDMARDs. It is important to monitor patients for thromboembolic events before and during JAK treatment.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/35/RU-60-46973.PMC9238315.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40556411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}